InterCure

The model outputs a Neutral rating for Intercure Ltd., scoring 48/100 at conviction 1 of 5. The composite is a fixed blend of four pillars — fundamentals at 35 percent, regulatory at 25, market at 25, and editorial at 15 — and each contribution is inspectable. The strongest contribution comes from the regulatory pillar at 62, and pulls the composite into the middle of the band. Editorial lags at 30, softening what would otherwise be a stronger reading.

Pillar-level, the record reads as reported revenue growth of 23.9 percent year over year, an operating margin of 0.0 percent, a filing cadence of 2 regulator events in the trailing 90 days. Each of those data points tethers the Neutral conclusion to observable evidence. Every input flowing into the pillar table comes from primary regulatory filings, licensed fundamentals data, and institutional pricing feeds, filtered through CIN newsroom density. The 336-ticker CIN universe is scored deterministically, so Intercure Ltd. can be compared against the global cannabis coverage universe on identical inputs, refreshed on the ingest cycle.

The rating turns on regulatory pace. Filings landing at above the trailing-90-day cadence, combined with an unblemished enforcement record, would carry Intercure Ltd. above the Neutral anchor; a lull would soften the read.